Retinoblastoma Treatment in India
Get Retinoblastoma Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Retinoblastoma Treatment in UAE
Retinoblastoma Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Retinoblastoma is a rare but life-threatening intraocular malignancy primarily affecting children under five, requiring rapid, multidisciplinary oncologic and ophthalmic intervention to preserve life, vision, and the eye itself. With globe-salvage rates exceeding 95% for early-stage disease and overall survival rates above 97% in high-volume centers, retinoblastoma treatment in India and the UAE represents a gold standard of pediatric oncology care delivered at a fraction of Western costs. GAF Healthcare connects international families to JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, providing end-to-end medical coordination, visa facilitation, and compassionate family support throughout this critical journey.
Hospital Stay: 3–10 days per treatment cycle (varies by modality: chemotherapy admission, intra-arterial infusion, or enucleation surgery) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (depending on treatment protocol: 2 weeks post-enucleation; up to 6 weeks for completion of initial systemic chemotherapy induction cycle) • Success Rate: 95–98% overall survival (developed-world stage); 85–95% globe salvage rate for Groups A–D (International Classification of Retinoblastoma)
What Is It?
Retinoblastoma is a malignant tumor arising from immature retinal precursor cells (retinoblasts), driven by biallelic inactivation of the RB1 tumor suppressor gene located on chromosome 13q14. It accounts for approximately 3% of all childhood cancers and is the most common primary intraocular malignancy in children, with a global incidence of roughly 1 in 16,000–18,000 live births. The tumor may be unilateral (60%) or bilateral (40%); bilateral disease is almost always heritable and associated with germline RB1 mutations, which also confer a significantly elevated lifetime risk of second primary malignancies including osteosarcoma and pineal gland tumors (trilateral retinoblastoma). Clinically, retinoblastoma presents most often as leukocoria (white pupillary reflex), strabismus, or less commonly orbital inflammation, decreased vision, or secondary glaucoma. Without treatment, the tumor can fill the vitreous cavity, extend through the optic nerve to the central nervous system, or metastasize hematogenously to bone marrow, bone, and liver — making early detection and prompt, specialized intervention absolutely critical to survival.
The physiological impact of retinoblastoma is multidimensional. Intraocularly, tumors destroy photoreceptors and inner retinal architecture, causing irreversible visual loss in the affected segments. Advanced disease leads to total retinal detachment, neovascular glaucoma, and phthisis bulbi. Extraocular extension — a far more common presentation in low-resource settings — dramatically worsens prognosis, with survival dropping below 50% in metastatic cases even with aggressive systemic chemotherapy. Children with germline mutations face not only bilateral ocular disease but also profound long-term oncologic surveillance needs and potential radiation-induced secondary sarcomas if external beam radiotherapy (EBRT) is used — a technique now largely abandoned in favor of globe-sparing focal and systemic strategies.
The modern standard of care for retinoblastoma is risk-stratified and multidisciplinary, guided primarily by the International Classification of Retinoblastoma (ICRB), which assigns eyes to Groups A through E based on tumor size, location, vitreous seeding, and subretinal spread. Group A and B tumors are managed with focal therapies — laser photocoagulation (transpupillary thermotherapy, TTT), cryotherapy, or plaque brachytherapy — often achieving cure without systemic chemotherapy. Groups C and D require systemic intravenous chemoreduction (carboplatin, vincristine, etoposide — the CVE protocol) combined with focal consolidation. Intra-arterial chemotherapy (IAC), delivered via superselective ophthalmic artery catheterization using melphalan, topotecan, or carboplatin, has revolutionized globe salvage for advanced Group D eyes, with salvage rates of 70–90% even for eyes previously considered enucleation candidates. Intravitreal chemotherapy (IViC) with melphalan or topotecan is now standard for refractory vitreous seeding. Group E eyes, and those failing conservative management, require enucleation — surgical removal of the eye — followed by histopathological risk stratification and adjuvant chemotherapy if high-risk features (post-laminar optic nerve involvement, massive choroidal invasion, anterior segment extension, or scleral breach) are identified.
Candidates
• ELIGIBLE PATIENTS — OPHTHALMOLOGIC AND ONCOLOGIC CRITERIA:
• Children with newly diagnosed unilateral or bilateral retinoblastoma confirmed by indirect ophthalmoscopy under examination under anesthesia (EUA) and RetCam digital fundus imaging
• ICRB Group A–D eyes in patients where globe salvage is the primary goal and systemic metastasis has been excluded
• ICRB Group E eyes, or failed prior treatment eyes, where enucleation with histopathologic risk stratification is indicated
• Children with heritable (germline) RB1 mutations requiring surveillance EUAs and genetic counseling for family members
• Patients with extraocular or metastatic retinoblastoma requiring high-dose chemotherapy with autologous stem cell rescue (HDC-ASCR) at specialized pediatric oncology centers
• Families seeking a second opinion or re-evaluation after primary treatment elsewhere
• REQUIRED DIAGNOSTIC WORKUP BEFORE TREATMENT:
• Examination Under Anesthesia (EUA) with binocular indirect ophthalmoscopy and RetCam III wide-field fundus photography — essential for ICRB group classification
• Ocular B-scan ultrasonography — to detect calcification (pathognomonic for retinoblastoma) and measure tumor dimensions
• MRI of the orbits and brain with gadolinium enhancement (3T MRI preferred) — to rule out optic nerve involvement, extraocular extension, and trilateral retinoblastoma (pineal/suprasellar tumors)
• Bone marrow aspiration and biopsy (both posterior iliac crests) — for metastatic staging in high-risk or advanced cases
• Lumbar puncture with CSF cytology — for CNS involvement assessment in high-risk cases
• Technetium-99m bone scintigraphy or PET-CT (FDG) — for systemic metastatic staging in extraocular disease
• Complete blood count, liver function tests, renal function tests, and audiogram (baseline before platinum-based chemotherapy)
• RB1 germline genetic testing via blood leukocyte DNA sequencing — mandatory for all bilateral cases and strongly recommended for unilateral cases with early age of onset or family history
• Fluorescein angiography (FA) — to map feeding vessels for focal laser or IAC planning
• CONTRAINDICATIONS / EXCLUSION CRITERIA:
• Uncontrolled systemic sepsis or active severe infection precluding general anesthesia
• Absolute contraindication to general anesthesia due to severe comorbid cardiopulmonary disease (rare in pediatric population; requires anesthesiology clearance)
• Carotid or ophthalmic artery anatomy precluding safe catheterization for IAC (relative; assessed by pre-procedure MR angiography)
• Documented allergy or prior severe hypersensitivity to chemotherapy agents in the proposed protocol (requires protocol modification, not absolute exclusion)
• Advanced metastatic disease with poor performance status where palliative intent must be established in consultation with the family and ethics team
Procedure
FOCAL OPHTHALMIC THERAPIES (Groups A–B; focal consolidation in C–D):
1. Laser Photocoagulation / Transpupillary Thermotherapy (TTT): Infrared diode laser (810 nm) delivered under indirect ophthalmoscopy or slit-lamp delivery system to small (≤3 mm base), posterior tumors away from the fovea and optic disc. Three sessions at 4-week intervals are typically required. TTT destroys tumor by hyperthermia (45–60°C) without the scatter damage of traditional photocoagulation. Best for small, flat Group A lesions.
2. Cryotherapy: Triple-freeze-thaw technique using a cryoprobe under indirect ophthalmoscopic guidance, applied transsclerally to tumors in the anterior retina (posterior tumors inaccessible). Achieves tumor destruction through ice-crystal-mediated cell lysis. Used for peripheral tumors unsuitable for laser and as consolidation after chemoreduction.
3. Plaque Brachytherapy (Episcleral Plaque Radiotherapy): Iodine-125 (I-125) or Ruthenium-106 (Ru-106) radioactive plaques sutured to the sclera overlying medium-sized tumors (up to 16 mm base) for 3–7 days, delivering a focal radiation dose of 40–45 Gy to the tumor apex while sparing surrounding ocular structures. Used for select Group B–C tumors not amenable to laser/cryo, or as salvage after IAC failure.
SYSTEMIC INTRAVENOUS CHEMOTHERAPY (CHEMOREDUCTION — Groups C–D, high-risk histology post-enucleation):
4. CVE Protocol (Carboplatin + Vincristine + Etoposide): The international standard first-line systemic chemoreduction regimen. Typically 6 cycles (21-day intervals) administered as inpatient infusions. Carboplatin dosing in infants is AUC-based (Calvert formula) given renal immaturity. Chemoreduction shrinks tumors to allow subsequent focal consolidation. High-risk histopathologic features post-enucleation (post-laminar optic nerve involvement >1.5 mm, massive choroidal invasion, anterior segment/scleral extension) mandate adjuvant chemotherapy (modified CVE × 4–6 cycles).
5. High-Dose Chemotherapy with Autologous Stem Cell Rescue (HDC-ASCR): Reserved for metastatic or CNS retinoblastoma. Stem cells are harvested after induction, the patient receives myeloablative conditioning (thiotepa-based regimens ± carboplatin/etoposide), followed by autologous stem cell infusion. Achieves durable remissions in a subset of metastatic patients when combined with aggressive intrathecal chemotherapy for CNS disease.
INTRA-ARTERIAL CHEMOTHERAPY (IAC) — ADVANCED GLOBE SALVAGE (Groups C–D; select Group E; recurrent disease):
6. Ophthalmic Artery Chemosurgery (OAC / Superselective IAC): A neurointerventional radiologist advances a microcatheter (typically 1.2–1.5 Fr Marathon or Sonic microcatheter) via femoral artery access through the internal carotid artery into the ophthalmic artery under fluoroscopic guidance, and infuses melphalan (3–7.5 mg), topotecan (1–2 mg), or carboplatin (30–50 mg) in a pulsatile fashion directly into the ocular circulation. This achieves intraocular drug concentrations 10–100× higher than systemic IV dosing with dramatically reduced systemic toxicity. Repeated every 3–4 weeks for 3–6 cycles. Globe salvage rates: 70–90% for Group D eyes. This is the signature advanced technique distinguishing elite centers from standard centers. Key complications include choroidal ischemia, ophthalmic artery vasospasm, periorbital edema, and rare stroke; managed by experienced teams with <1% serious neurological event rates.
7. Intravitreal Chemotherapy (IViC): Direct intravitreal injection of melphalan (20–30 mcg) or topotecan (20 mcg) to treat refractory or recurrent vitreous seeding — historically the most difficult aspect of retinoblastoma to control without enucleation. Modern prophylactic technique (cryotherapy to injection site, avoidance of reflux) has essentially eliminated risk of extraocular tumor seeding. 3–8 injections at 1–2 week intervals. Revolutionized management of diffuse vitreous seeding (previously a definitive enucleation indication).
SURGICAL INTERVENTION:
8. Enucleation: Surgical removal of the globe under general anesthesia. Indicated for ICRB Group E eyes, failed globe salvage, suspected extraocular extension, painful blind eye, or inability to monitor/treat adequately. The key surgical principle is obtaining maximum optic nerve length (>10 mm posterior stump) to reduce risk of cut-end involvement. An eviscerated primary orbital implant (hydroxyapatite or porous polyethylene, 16–20 mm) is placed at the time of enucleation for optimal prosthetic fitting and orbital volume maintenance. The child is fitted for a custom ocular prosthesis (artificial eye) beginning 4–6 weeks postoperatively, followed by serial implant exchange as the orbit grows.
9. External Beam Radiotherapy (EBRT): Now largely abandoned for primary retinoblastoma management due to the unacceptably high risk of radiation-induced secondary sarcomas (particularly in germline RB1 mutation carriers, where cumulative risk exceeds 35% at 30 years within the radiation field). Rarely used in exceptional salvage situations at specialized centers or for orbital and CNS disease.
EMERGING AND PRECISION MEDICINE APPROACHES:
10. Targeted Therapy and Immunotherapy (Investigational): CDK4/6 inhibitors, MDM2 antagonists, and immune checkpoint inhibitors are under active investigation in refractory/metastatic retinoblastoma given the immunologically cold tumor microenvironment. Enrollment in international clinical trials (e.g., COG ARET protocols) is available at select partnered centers.
Cost of Retinoblastoma Treatment: India vs. UAE
The cost of retinoblastoma treatment varies significantly depending on the treatment modality required (focal therapy, intra-arterial chemotherapy, systemic chemoreduction, or enucleation), the ICRB group of disease, the number of eyes involved, and the number of treatment cycles needed. India offers world-class retinoblastoma care — including advanced IAC by experienced neurointerventional teams — at 40–60% lower cost than equivalent care in the UAE, while the UAE provides premium hospital environments with the added convenience of shorter flight connections from Europe, the Middle East, and Africa. The figures below represent estimated all-inclusive costs per treatment course (initial workup, primary treatment, and acute follow-up EUAs within the same episode of care); repeat chemotherapy cycles and long-term surveillance costs are additional.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $3,000 – $18,000 | ~53% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $7,000 – $38,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL PREPARATION (2–4 weeks before travel):
• Step 1: Submit medical records to GAF Healthcare (RetCam images, prior EUA reports, MRI, genetic testing results if available). Our assigned pediatric oncology coordinator reviews records within 48 hours and obtains a written treatment plan and cost estimate from the selected hospital team.
• Step 2: GAF Healthcare assists with e-Medical Visa application for India (typically approved in 3–5 business days; valid for 60 days, triple-entry) or UAE entry visa coordination. Passport copies, photographs, and the hospital invitation letter are all facilitated by our team.
• Step 3: Pre-travel lab work (CBC, CMP, audiogram, RB1 genetics if not done) may be performed locally and results shared digitally with the treating team to avoid duplication and reduce in-country diagnostic delays.
• Step 4: GAF Healthcare arranges airport reception, private ambulance or medical-grade vehicle transfer to the hospital, and family accommodation in a partner serviced apartment or hospital guest house within 10–15 minutes of the treatment center.
PHASE 2 — ARRIVAL AND DIAGNOSTIC CONFIRMATION (Days 1–3):
• Day 1: Hospital admission, pediatric oncology and ophthalmology consultations, nursing assessment, anesthesia pre-assessment for EUA.
• Day 2: Examination Under Anesthesia (EUA) with RetCam III imaging, B-scan ultrasonography, and MRI orbits/brain under same anesthetic (to minimize number of general anesthetics). Staging and ICRB classification finalized.
• Day 3: Tumor board multidisciplinary team (MDT) meeting — pediatric oncologist, vitreoretinal/ocular oncology surgeon, neurointerventional radiologist, radiation oncologist, pathologist, and geneticist review all imaging and agree on individualized treatment plan. Family counseling session conducted with a dedicated pediatric psychosocial support worker.
PHASE 3A — FOCAL THERAPY PATHWAY (Groups A–B; typically 3–5 days total in-country for initial session):
• Day 3–4: Laser photocoagulation (TTT) or cryotherapy performed under general anesthesia. Procedure duration: 30–60 minutes. Child recovered in PICU for 2–4 hours post-anesthesia, then transferred to pediatric ward.
• Day 5–7: Discharge with topical steroid and antibiotic drops. Follow-up EUA scheduled at 4 weeks (family may return home and come back, or remain if bilateral disease requires second-eye treatment).
• Milestone: Fit to fly 48–72 hours post-focal-therapy session, once child is tolerating oral feeds, pain-free, and anesthesia team has cleared. Total stay: approximately 5–7 days.
PHASE 3B — INTRA-ARTERIAL CHEMOTHERAPY (IAC) PATHWAY (Groups C–D; 3–6 cycles, each requiring 3–5 days in-country):
• Cycle Day 1: Admission. Pre-hydration, anti-emetic prophylaxis, anesthesia induction. Neurointerventional radiology suite: femoral artery access under fluoroscopy, microcatheter navigation to ophthalmic artery (30–60 minutes), pulsatile melphalan/topotecan infusion (30–45 minutes). Total anesthesia time: 90–120 minutes.
• Cycle Day 1 (post-procedure): 4–6 hours observation in PACU/PICU for hemostasis (femoral access site), ocular monitoring, anti-emesis management. Most children mobilize same day.
• Cycle Day 2–3: Ophthalmologic review, wound check, CBC monitoring, discharge planning.
• Cycle Day 3–4: Discharge. Family returns home or to accommodation between cycles (cycles repeat every 3–4 weeks). GAF Healthcare coordinates return travel and re-admission scheduling.
• Post-cycle EUAs: Performed at 4 weeks after each IAC cycle to assess tumor response. Treatment plan adapted based on response.
• Milestone: Fit to fly 48–72 hours post-IAC cycle, once femoral access site is healed, child is systemically stable, and no significant choroidal ischemia is identified at post-procedure fundus assessment.
PHASE 3C — SYSTEMIC IV CHEMOTHERAPY (CHEMOREDUCTION) PATHWAY (Groups C–D, high-risk post-enucleation; 6 cycles):
• Each 21-day cycle requires 3–5 days inpatient admission for IV carboplatin, vincristine, and etoposide infusion with supportive care (anti-emetics, G-CSF if neutropenic, hydration).
• Nadir CBC monitoring at Days 10–14; GAF Healthcare coordinates outpatient CBC checks at a local lab if family is staying in-country between cycles, or provides detailed instructions for monitoring at home country if international travel between cycles is feasible.
• EUAs with focal consolidation (laser, cryo) scheduled between cycles 2–3 and at cycle 6 completion.
• Total treatment duration: 18–24 weeks for a full 6-cycle course.
PHASE 3D — ENUCLEATION PATHWAY (Group E; typically 5–8 days in-country):
• Day 1: Admission, pre-operative assessment, anesthesia review.
• Day 2: Enucleation under general anesthesia (45–60 minutes). Hydroxyapatite orbital implant placed; conjunctiva and Tenon's capsule closed in layers. Conformer (clear acrylic spacer) placed over implant. Pressure dressing applied.
• Days 3–5: Inpatient recovery; pain managed with paracetamol ± opioid PRN (typically opioid-free by Day 2). Pressure dressing removed Day 3; conformer inspected. Pathology specimen sent for urgent histopathologic risk stratification.
• Days 5–7: Histopathology result review. If high-risk features confirmed, adjuvant chemotherapy plan communicated and scheduled. Family counseling on prosthetic eye fitting (initiated 4–6 weeks post-op).
• Discharge Day 7–8: Oral antibiotics, topical antibiotic ointment to socket. Genetic counseling referral confirmed.
• Milestone: Fit to fly 10–14 days post-enucleation, once socket is healing appropriately, orbital swelling is resolving, and no immediate adjuvant chemotherapy admission is required.
PHASE 4 — FOLLOW-UP AND SURVEILLANCE (Ongoing, with telemedicine support via GAF Healthcare):
• EUAs every 4–6 weeks during active treatment, then every 3 months for Year 1, every 6 months for Years 2–3, annually thereafter for unilateral non-germline cases.
• Germline mutation carriers: Annual MRI brain surveillance to age 5 (trilateral RB screening), annual ophthalmology review for life, systemic oncologic surveillance per international guidelines (Children's Oncology Group ARET protocols).
• GAF Healthcare provides telemedicine coordination between the treating hospital and the family's local pediatrician/oncologist for all follow-up, report sharing, and emergency guidance.
Risks & Considerations
Retinoblastoma treatment carries a specific and carefully characterized risk profile for each modality that families must understand before proceeding. For laser photocoagulation and cryotherapy, risks include retinal scarring, macular damage causing permanent visual loss if tumors are in or near the fovea, retinal detachment (uncommon, <5%), and the theoretical but extremely rare risk of tumor seeding with cryotherapy if technique is imprecise. Repeated general anesthesia in young children carries cumulative neurodevelopmental exposure risk; modern protocols minimize anesthetic duration and use total intravenous anesthesia (TIVA) with agents like propofol and remifentanil to reduce this burden. For intra-arterial chemotherapy (IAC), the principal risks include choroidal ischemia (leading to visual field loss or, rarely, choroidal atrophy in 5–15% of treated eyes depending on infused drug and dose), ophthalmic artery vasospasm (managed intra-procedurally with topical nitroglycerin or papaverine), periorbital edema (transient, resolving in 1–2 weeks), neutropenia (mild, given low systemic drug exposure), and — very rarely (<0.5% at experienced centers) — ischemic stroke from catheter-related ICA spasm or thromboembolic events. Intravitreal chemotherapy risks include hemorrhagic vitreous, cataract, retinal pigment epithelium disruption, and historically (now largely eliminated by modern injection technique) extraocular tumor seeding. Systemic carboplatin-based chemotherapy carries risks of myelosuppression (neutropenic fever requiring inpatient management), cumulative ototoxicity (high-frequency sensorineural hearing loss, particularly with carboplatin in infants; mandatory audiologic monitoring), peripheral neuropathy from vincristine, and very rare secondary hematologic malignancy (secondary AML from etoposide, estimated <1% cumulative incidence). Enucleation is irreversible loss of the eye; psychological impact on the child and family requires dedicated psychosocial support and early prosthetic rehabilitation. Orbital implant complications include extrusion (<2% with hydroxyapatite), implant migration, conjunctival thinning, and socket contraction. For children with germline RB1 mutations, any radiotherapy substantially increases secondary malignancy risk (especially osteosarcoma, soft tissue sarcoma) and must be avoided or used only in life-threatening situations with full family counseling. Trilateral retinoblastoma (pineal/suprasellar primitive neuroectodermal tumor in germline carriers) carries a grave prognosis and underscores the critical importance of brain MRI surveillance. All risks are discussed in detail during the pre-treatment MDT family counseling session coordinated by GAF Healthcare's assigned case manager.
Top Hospitals for Retinoblastoma Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
All India Institute of Medical Sciences (AIIMS)
New Delhi, India
Christian Medical College (CMC)
Vellore, India
Manipal Hospitals Dwarka
New Delhi, India
Top Doctors for Retinoblastoma Treatment
Internationally trained specialists in Ophthalmology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Abhishek Hoshing
MBBS, MS (Ophthalmology), Fellowship (Advanced Ophthalmic Subspecialties)
Ophthalmologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
9+ Yearsof experience
Dr. Abhishek Hoshing is a Senior Consultant Ophthalmologist at Apollo Hospitals, Navi Mumbai, bringing over nine years of dedicated experience in eye care. He works across a wide spectrum of ophthalmic conditions — from everyday refractive concerns to complex retinal and corneal disorders — and is particularly known for his expertise in cataract surgery, glaucoma management, and the treatment of diabetic eye disease. Dr. Hoshing completed both his MBBS… Read more
Dr. Ajit Babu Majji
MBBS, MD Ophthalmology, FRCS, Vitreo-Retinal Surgery Fellowship
Vitreo-Retinal Surgeon & Ophthalmologist
Yashoda Hospitals, Hi-Tech City, Hyderabad, India
37+ Yearsof experience
Dr. Ajit Babu Majji is one of India's most experienced vitreo-retinal specialists, with over 37 years dedicated to protecting and restoring the sight of patients from across the country and around the world. Based at Yashoda Hospitals in Hyderabad's Hi-Tech City, he leads the Vitreo-Retinal Services unit and brings a rare combination of surgical precision, clinical depth, and genuine warmth to every patient he sees. His particular focus is on complex… Read more
Dr. Akshi Sharma
MBBS, MS (Ophthalmology), DNB (Ophthalmology), Long-Term Fellowship — Vitreo-Retina, Uvea, ROP & Cataract
Ophthalmologist & Vitreo-Retina Specialist
The Sight Avenue Eye Hospital, New Delhi, India
10+ Yearsof experience
Dr. Akshi Sharma is an ophthalmologist based in New Delhi with a focused expertise in diseases of the retina and vitreous. Over more than a decade of clinical practice, she has built a reputation for managing complex conditions like retinal detachment, macular holes, diabetic retinopathy, and age-related macular degeneration — conditions that can be sight-threatening if not caught and treated in time. Her academic journey reflects a commitment to… Read more
Dr. Aniel Malhotra
MBBS, MS (Ophthalmology), DOMS (Diploma in Ophthalmic Medicine and Surgery)
Ophthalmologist
Indraprastha Apollo Hospital, New Delhi, India
35+ Yearsof experience
Dr. Aniel Malhotra is one of Delhi's most experienced eye specialists, bringing over 35 years of dedicated practice in ophthalmology to his patients at Indraprastha Apollo Hospital. He holds an MBBS, an MS in Ophthalmology, and a DOMS — a combination that reflects both the depth and breadth of his formal training. Over the decades, he has built a reputation for handling some of the most complex eye conditions with calm precision and genuine care. His… Read more
Dr. Annam Sridhar
MBBS, MS, MD
Ophthalmologist
Apollo Hospital, Jubilee Hills, Hyderabad, India
28+ Yearsof experience
Dr. Annam Sridhar is a senior ophthalmologist based at Apollo Hospital, Jubilee Hills, Hyderabad, with more than 28 years of hands-on experience in eye care. His core strengths lie in corneal ophthalmology, refractive laser surgery, and cataract management — areas where patients rely on both technical precision and steady, reassuring guidance. Over the decades, he has built a reputation for being thorough, approachable, and genuinely invested in each… Read more
Frequently Asked Questions — Retinoblastoma Treatment
The cost of retinoblastoma treatment depends heavily on the treatment modality required, the number of eyes involved, and the number of cycles needed. In India, a complete treatment course — covering diagnostic workup under anesthesia (EUA with RetCam, MRI, B-scan), the primary treatment modality (laser/cryo for early-stage, intra-arterial chemotherapy for advanced Group C–D, or enucleation with orbital implant), hospital stay, anesthesia, and immediate follow-up EUAs — typically ranges from approximately USD 3,000 to USD 18,000. A single IAC cycle in India costs approximately USD 2,500–5,000; a full 6-cycle systemic chemoreduction course ranges from USD 8,000–18,000. In the UAE (Dubai or Abu Dhabi), equivalent care at JCI-accredited and DHA-licensed centers ranges from approximately USD 7,000 to USD 38,000, reflecting higher operational costs, premium hospital environments, and the UAE's elevated cost of living. India is generally 40–60% less expensive than the UAE for equivalent clinical expertise. Both destinations offer access to experienced ocular oncology teams capable of advanced IAC, intravitreal chemotherapy, and multidisciplinary pediatric oncology protocols. GAF Healthcare provides a transparent, itemized cost estimate for your child's specific staging and treatment plan before any commitment is made.
The safe duration of stay in the treatment country depends on which treatment modality your child receives. For focal therapy only (laser photocoagulation or cryotherapy for early Group A–B disease), children are typically fit to fly 48–72 hours after the procedure, once the post-anesthesia recovery is complete and there are no signs of retinal complication — making the total in-country stay approximately 5–7 days. For a single cycle of intra-arterial chemotherapy (IAC), children are generally cleared to fly 48–72 hours after the procedure, assuming the femoral access site is closed and healing, there is no significant choroidal ischemia, and the child is systemically stable — a total per-cycle stay of approximately 4–5 days. Families receiving multiple IAC cycles (typically 3–6 cycles at 3–4 week intervals) must either remain in-country throughout or travel home between cycles and return; GAF Healthcare helps families plan both options. For enucleation, the safe fly-home milestone is typically 10–14 days post-surgery, once the orbital socket is healing well, swelling is reducing, and there are no wound complications. For systemic intravenous chemoreduction (CVE protocol), each cycle requires 3–5 days inpatient and then monitoring through the nadir (Days 10–14 post-chemo); families planning to travel home between cycles should do so only after Day 14 CBC confirmation and medical clearance, meaning a minimum of 14 days per cycle before return flight. GAF Healthcare's case manager coordinates the formal fit-to-fly medical clearance letter required by most airlines for pediatric oncology patients traveling after treatment.
Retinoblastoma has one of the highest survival rates of any childhood cancer when treated promptly at a specialized, high-volume center — a fact that makes access to expert care the single most critical determinant of outcome. In developed-world settings, and at the JCI/NABH-accredited centers in India and JCI/DHA-licensed centers in the UAE that GAF Healthcare works with, the overall survival rate for retinoblastoma exceeds 97–98%. For intraocular disease (no extraocular extension), survival approaches 99–100%. For extraocular disease (orbital or regional lymph node involvement), survival drops to 60–80% with aggressive multimodal treatment. For metastatic CNS or hematogenous disease, survival with high-dose chemotherapy and autologous stem cell rescue ranges from 30–50% in current series. Beyond survival, the other critical metric is globe (eye) salvage — preserving the eye and maximizing residual vision. Globe salvage rates by ICRB group at expert centers using IAC and intravitreal chemotherapy are: Group A: >99%; Group B: 95–99%; Group C: 85–95%; Group D: 70–90%; Group E: 0–30% (enucleation is the standard). Visual outcomes depend on tumor proximity to the fovea and optic disc: eyes with macular-sparing disease can retain useful central vision (20/40 or better), while eyes with foveal tumors typically retain only peripheral vision even after successful tumor control. It is important to note that success rates at expert centers in India and the UAE — where teams perform high volumes of retinoblastoma cases annually — are comparable to those reported by leading institutions in the United States and Europe, while costs are a fraction of Western prices.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support designed to eliminate the logistical burden from families during what is inevitably a highly stressful time.
VISA AND TRAVEL DOCUMENTATION:
• India: GAF Healthcare prepares and submits the e-Medical Visa application on behalf of the patient and up to two accompanying guardians. The e-Medical Visa is issued by the Indian government within 3–5 business days, is valid for 60 days with triple-entry, and permits the patient to receive treatment at recognized hospitals. We provide the mandatory hospital appointment letter, invitation letter, and all supporting documentation required by the Indian Embassy or online portal. For patients requiring extended stays beyond 60 days (e.g., full 6-cycle chemoreduction courses), we coordinate visa extension applications through the hospital's international patient services office and liaise with the Foreigners Regional Registration Office (FRRO) on the family's behalf.
• UAE (Dubai / Abu Dhabi): Citizens of most Western European, GCC, and many Asian countries receive visa-on-arrival or visa-free entry to the UAE for 30–90 days. GAF Healthcare confirms eligibility for each family's nationalities in advance and, where a pre-arranged medical entry visa is required, coordinates the application through our UAE hospital partners who hold DHA (Dubai Health Authority) facilitation approvals. We also provide guidance on the UAE's Golden Visa pathway for patients requiring extended treatment.
AIRPORT AND GROUND TRANSFERS:
• Private, air-conditioned vehicle or medical-grade ambulance (if medically indicated) meets the family at the arrivals hall with a named GAF Healthcare representative holding signage — eliminating the confusion of navigating a new country with a sick child. Child-appropriate vehicle seating and medical-grade portable equipment are available on request.
DEDICATED INTERPRETERS AND CULTURAL LIAISONS:
• Language support is available in Arabic, French, Russian, Swahili, Bangla, Nepali, and over 20 additional languages through GAF Healthcare's interpreter network. Interpreters accompany the family for all medical consultations, EUAs, and discharge counseling sessions to ensure no clinical information is lost in translation.
ACCOMMODATION FOR PATIENT ATTENDANTS:
• GAF Healthcare has negotiated preferred rates at partner serviced apartments, family suites, and hospital guest houses located within 10–15 minutes of all treatment hospitals in Chennai, Mumbai, Delhi, Hyderabad, Bangalore, Dubai, and Abu Dhabi. Options are available for all budgets, from affordable hostel-standard family rooms to premium serviced apartments with kitchen facilities — critically important for families staying several weeks during chemotherapy cycles. Halal catering, child-friendly meal delivery, and laundry services are coordinated on request.
ONGOING CASE MANAGEMENT AND TELEMEDICINE:
• Each family is assigned a single dedicated GAF Healthcare case manager who is reachable via WhatsApp, email, and phone 16 hours a day, 7 days a week throughout the treatment episode. The case manager coordinates all appointment scheduling, inter-departmental communication, financial counseling, and post-discharge telemedicine follow-up between the treating hospital and the family's home-country physician.
Patients Also Explore
Other treatments commonly sought by patients considering Retinoblastoma Treatment.
Rhinoplasty (Nose Job)
Cosmetic Surgery
Liposuction
Cosmetic Surgery
Cochlear Implant
ENT
Hyperthyroidism Treatment
ENT